SecBot SecBot

IMVT

Immunovant, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001764013 Biotech & Drug Discovery
$28.49 +0.08 (+0.28%)
Oct 26 4:00 PM ET · prev $28.41
Market cap
$6.0B
Mid cap
Consensus
Buy
78% Buy or better · 23 analysts
Median target
$48.50
+70% · range $30.00–66.00
Next earnings
Nov 9
in 14 days · EPS est. −$0.72
1 year
+32.9%
from $21.43 · Oct 27
30 days
−14.9%
from $33.49
52-week range
$21.43–44.96
−37% from high · low Oct 27
Avg volume 20D
1.36M
shares / day
Short interest
17.42M
≈8.4% of shares · +0.9%
Days to cover
9.6
at average volume
Insider net
-$12.6M
0 buyers · 7 sellers · since May 20
New fund stakes
2
Q2 2026 13F · 2 exits
SecBot read BEARISH 1 report · 90 days
Balance 1 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 9, 2026
Strongest BEARISH Immunovant reported a Q1 FY2027 net loss of $153.2M ($-0.75/share), which was a 22.2% miss vs the $-0.61…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $12.6M.

  • InstitutionsBULLISH

    Q2 2026: 25 added (2 new), 14 trimmed or exited. Largest new: D. E. Shaw & ., $47.8M, Millennium Management $12.7M.

  • AnalystsBULLISH

    18 of 23 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.526 → −$0.722 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.9% to 17.42M shares. 9.6 days to cover, ≈8.4% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
2
exits
$60.5M
in new stakes
FundMoveSharesValue
FARALLON CAPITAL MANAGEMENT, L.L.C.DOUBLED5,805,000$223.7M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED1,829,210$70.5M
D. E. Shaw & Co., Inc.NEW1,240,654$47.8M
BANK OF AMERICA CORP /DE/ADD1,181,452$45.5M
SUSQUEHANNA INTERNATIONAL GROUP, LLPADD1,022,513$39.4M
Aberdeen Group plcTRIM857,030$33.0M
RENAISSANCE TECHNOLOGIES LLCDOUBLED726,800$28.0M
Nuveen, LLCDOUBLED602,046$23.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 78% rate it Buy or better
Strong Buy9Buy9Hold5Sell0Strong Sell0
12-month targets · 16 analysts

Price is below the lowest target. Median implies +70%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 4, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Jun 30, 2026Citigroup
MAINTAIN
MAINTAINBuy
May 26, 2026Guggenheim
MAINTAIN
MAINTAINBuy
May 22, 2026Truist Securities
MAINTAIN
MAINTAINHold
May 21, 2026B of A Securities
MAINTAIN
MAINTAINBuy
May 21, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$12.6M
sold · 7 insiders
DateInsiderTypeValue
Oct 21, 2026
Stout Jay S
Chief Technology Officer
SELL$75.1K
Oct 7, 2026
Van Tuyl Christopher
Chief Legal Officer
SELL$42.5K
Oct 7, 2026
Gloria Melanie
Chief Operating Officer
SELL$71.8K
Oct 7, 2026
Stout Jay S
Chief Technology Officer
SELL$70.9K
Oct 7, 2026
Stout Jay S
Chief Technology Officer
SELL$51.2K
Oct 2, 2026
Venker Eric
Chief Executive Officer
SELL$119.6K
Oct 1, 2026
Venker Eric
Chief Executive Officer
TO ISSUER$2.9M
Oct 1, 2026
Venker Eric
Chief Executive Officer
EXERCISE$1.3M

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.72
EPS estimate, this quarter
−37%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.72-$0.76–-$0.70-37.3%$0.00
Next Q-$0.67-$0.77–-$0.53-50.5%$0.00
Current FY-$2.84-$3.05–-$2.52+0.0%$0.00
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
17,416,613
shares short
+0.9%
vs prior settlement
9.6
days to cover
≈8.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 Insider
Stout Jay S sold 2,595 shares
Chief Technology Officer @ $28.94 ($75.1K)
Oct 7, 2026 Insider
Van Tuyl Christopher sold 1,327 shares
Chief Legal Officer @ $32.06 ($42.5K)
Oct 7, 2026 Insider
Gloria Melanie sold 2,241 shares
Chief Operating Officer @ $32.06 ($71.8K)
Aug 19, 2026 Other
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Aug 6, 2026 SEC
Immunovant reported a Q1 FY2027 net loss of $153.2M ($-0.75/share), which was a 22.2% miss vs the $-0.61 consensus…
8-K — Impact 6/10
Jul 24, 2026 SEC
Two C-suite insiders at Immunovant (CFO and CTO) sold a combined $374K in open-market sales on July 23, 2026, at…
CLUSTER — Impact 2/10
Jun 30, 2026 Inst.
FARALLON CAPITAL MANAGEMENT, L.L.C. — DOUBLED
5,805,000 shares ($223.7M)
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — DOUBLED
1,829,210 shares ($70.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
IMVT Q2 2027 Earnings Scheduled — 2026-11-09
Recent
Sep 14, 2026
Clinical Trial
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Phase 3 · TERMINATED
Aug 19, 2026
Press release
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors…
Aug 13, 2026
Clinical Trial
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
Phase 2 · COMPLETED
Aug 11, 2026
Clinical Trial
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
Phase 2 · TERMINATED
Aug 11, 2026
Clinical Trial
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2 · TERMINATED

SecBot reports

12 filings · 1 bullish · 1 bearish · 1 mixed · 9 neutral
All IMVT filing & press-release reports (12)